RELATIVE VALUE OF EVIDEM MCDA FRAMEWORK FOR REFLECTIVE DRUG EVALUATION AMONG HOSPITAL PHARMACISTS IN PORTUGAL

Author(s)

Mirco A1, Paulino E1, Farinha MH1, Gil A2, Shepherd J3, Badia FJ3
1South and Autonomous Regions Branch-Pharmaceutical Society Portugal, Lisbon, Portugal, 2Omakase Consulting, BARCELONA, Spain, 3Omakase Consulting, Barcelona, Spain

OBJECTIVES: To assess the value of applying reflective MCDA to health technology assessments by hospital pharmacotherapeutic committees in Portugal.

METHODS: The EVIDEM MCDA framework was used to assess the feasibility of using this methodology among pharmacotherapeutic committees in Portugal. Firstly, EVIDEM quantitative criteria were weighted using a direct rating scale (1: low relative importance; 5: high relative importance). Secondly, an example assessment of an orphan drug indicated for Gaucher Disease was used to rate the evidence matrix and numbers were used to establish a reflective discussion among participants. Finally, a satisfaction questionnaire was shared to collect participant’s opinions on the feasibility of using MCDA methodology.

RESULTS:

Twelve hospital pharmacists from Portugal participated in the study. Criteria considered most important (≥4.0 points) were: “disease severity” (4,7), “comparative efficacy/effectiveness” (4,4) and “comparative safety/tolerability” (4,1). Criteria considered less important (≤3.0) were: “comparative other medical costs” (2,9), “comparative non-medical costs” (2,9) and “size of affected population” (2,0).

Participants did not consider “size of affected population” an important criterion, as they use budget impact numbers to know the population intended to be treated with a new drug.

All participants considered that MCDA would be useful in hospital drug assessments by complementing the value analysis structuring evidence in an evidence matrix and by discussing the assessment results among all members of the pharmacotherapeutic committee. Most of the participants (90%) considered that MCDA would be useful to make explicit all elements of value assessments, to weigh the assessment criteria and to consider contextual aspects of decision making.

All participants considered that MCDA could provide value to health technology value assessments focusing on healthcare making.

CONCLUSIONS: This feasibility study suggests that Portuguese hospital pharmacists would consider the application of MCDA methodology in health technology assessments could be useful compared to current evaluation process.

Conference/Value in Health Info

2018-11, ISPOR Europe 2018, Barcelona, Spain

Value in Health, Vol. 21, S3 (October 2018)

Code

PHP203

Topic

Health Policy & Regulatory, Health Service Delivery & Process of Care

Topic Subcategory

Hospital and Clinical Practices, Reimbursement & Access Policy

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×